Seeking Alpha

A Nevada jury awards $14M to a colonoscopy patient who blames his hepatitis on reusable vials of...

A Nevada jury awards $14M to a colonoscopy patient who blames his hepatitis on reusable vials of Propofol, marking the third verdict against Baxter International (BAX -1.2%) and Teva Pharmaceuticals (TEVA +0.7%) over an outbreak in the state tied to use of the drug. An attorney for Teva passes off blame to doctors: "It’s not a vial problem... it’s a practice problem."
From other sites
Comments (1)
  • coonhound
    , contributor
    Comment (1) | Send Message
     
    The story is incomplete, the jury is awarding 100's of millions of dollars to patients. I was an anesthesiologist for 30 years and Propofol was never in reusable vials. The jury had a chance to stick it to big business and they did. They should have stuck it to the anesthetist who was unaware of the germ theory of disease.
    11 Oct 2011, 02:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs